Azathioprine Mechanism Of Action In Myasthenia Gravis

Inhibition of the cell cycle azathioprine cyclophosphamide methotrexate and mycophenolate mofetil. Azathioprine also may integrate into nucleic acids resulting in chromosome breakage nucleic acid malfunction or the synthesis of faulty proteins.

Myasthenia Gravis Neurology Internal Medicine Correlations And

Side effects necessitated discontinuation of treatment in only four patients.

Azathioprine mechanism of action in myasthenia gravis. It reduces the production of antibodies by damping down the activity of the body s immune system. Introduction myasthenia gravis mg may be due to a genetic defect intoxication or most frequently autoimmune mechanisms 1. Mechanism of action azathioprine decreases the metabolism of purines and may inhibit dna and rna synthesis as well.

The mechanisms of action of immunosuppressant drugs in mg fall into three main categories. Mild immunosuppression with azathioprine is feasible and effective in such a patient without worsening myasthenia gravis or primary sclerosing cholangitis. Azathioprine is a type of medicine called an immunosuppressant.

Data in a limited number of clinical trials suggest that azathioprine may be beneficial for the treatment of myasthenia gravis when used in combination with glucocorticoids in patients who are not adequately controlled with pyridostigmine myasthenia gravis study group 1993 palace 1998. 6 thioguanine triphosphate a metabolite of azathioprine modulates activation of rac1 when costimulated with cd28 inducing t cell apoptosis. This helps messages getting through from the nerves to the muscles and muscle strength improves.

Other immunosuppressants that have been used to treat myasthenia gravis. The enzyme thiopurine s methyltransferase tpmt is responsible for various activation and deactivation steps in azathioprine s mechanism of action. The first metabolic step that azathioprine undergoes in the body is the conversion to 6 mercaptopurine 6 mp.

The mechanism of action is not known but is probably non specific down regulation of antibody production. Once uniformly disabling and sometimes fatal mg can be managed effectively with therapies that include anticholinesterase agents rapid immunomodulatory therapies. Azathioprine s mechanism of action is not entirely understood but it may be related to inhibition of purine synthesis along with inhibition of b and t cells.

See pharmacokinetics which is itself an immunosuppressant prodrug. Introduction myasthenia gravis mg is an autoimmune disorder of the postsynaptic neuromuscular junction characterized by fluctuating weakness involving variable combinations of ocular bulbar limb and respiratory muscles. Most recently a subcutaneous form of the preparation is available and may be used as an alternative treatment option especially in patients with limited intravenous access.

Twenty seven patients with myasthenia gravis have been treated with azathioprine in conjunction with pyridostigmine and prednisolone for a total of 138 patient years.

Emerging Therapies For Autoimmune Myasthenia Gravis Towards